MARK JEREMY HUNT

Dr. MARK JEREMY HUNT


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1999 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
LLLisa A. Lione
Lisa A. Lione
RCRebecca J. Carter
Rebecca J. Carter
MHMARK JEREMY HUNT
MARK JEREMY HUNT
GBGillian P. Bates
Gillian P. Bates
AMA. Jennifer Morton
A. Jennifer Morton
SDStephen B. Dunnett
Stephen B. Dunnett
Cognitive decline is apparent in the early stages of Huntington's disease and progressively worsens throughout the course of the disease. Expression of the human Huntington's disease mutation in mice (R6/2 line) causes a progressive neurological phenotype with motor symptoms resembling those seen in Huntington's disease. Here we describe the cognitive performance of R6/2 mice using four different tests (Morris water maze, visual cliff avoidance, two-choice swim tank, and T-maze). Behavioral testing was performed on R6/2 transgenic mice and their wild-type littermates between 3 and 14.5 weeks of age, using separate groups of mice for each test. R6/2 mice did not show an overt motor phenotype until ∼8 weeks of age. However, between 3.5 and 8 weeks of age, R6/2 mice displayed progressive deterioration in specific aspects of learning in the Morris water maze, visual cliff, two-choice swim tank, and T-maze tasks. The age of onset and progression of the deficits in the individual tasks differed depending on the particular task demands. Thus, as seen in humans with Huntington's disease, R6/2 mice develop progressive learning impairments on cognitive tasks sensitive to frontostriatal and hippocampal function. We suggest that R6/2 mice provide not only a model for studying cognitive and motor changes in trinucleotide repeat disorders, but also a framework within which the functional efficacy of therapeutic strategies aimed at treating such diseases can be tested.

1 December 2006 in Biological Psychiatry
Verified
Journal Article
Closed access
MHMARK JEREMY HUNT
MARK JEREMY HUNT
BRBeryl Raynaud
Beryl Raynaud
RGRene Garcia
Rene Garcia

1 June 2017 in Trends in Neurosciences
Verified
Journal Article
Closed access
MHMARK JEREMY HUNT
MARK JEREMY HUNT
NKNancy J. Kopell
Nancy J. Kopell
RTRoger D. Traub
Roger D. Traub
MWMiles A. Whittington
Miles A. Whittington

1 September 2000 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
RCRebecca J. Carter
Rebecca J. Carter
MHMARK JEREMY HUNT
MARK JEREMY HUNT
AMA. Jennifer Morton
A. Jennifer Morton

17 July 2013 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MHMARK JEREMY HUNT
MARK JEREMY HUNT
SKStefan Kasicki
Stefan Kasicki
Distinct frequency bands can be differentiated from neuronal ensemble recordings, such as local field potentials or electrocorticogram recordings. Recent years have witnessed a rapid acceleration of research examining how N-methyl-D-aspartate receptor (NMDAR) antagonists influence fundamental frequency bands in cortical and subcortical brain regions. Herein, we systematically review findings from in vivo studies with a focus on delta, theta, gamma and more recently identified high-frequency oscillations. We also discuss some of the current hypotheses that are considered to account for the actions of NMDAR antagonists on these frequency bands. The data emphasize a close relationship between altered oscillatory activity and NMDAR blockade, with both local and large-scale networks accounting for their effects. These findings may have fundamental implications for the psychotomimetic effects produced by NMDAR antagonists.

1 February 2005 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
AMA. Jennifer Morton
A. Jennifer Morton
MHMARK JEREMY HUNT
MARK JEREMY HUNT
AHAngela K. Hodges
Angela K. Hodges
PLPaul D. Lewis
Paul D. Lewis
ARAmanda J. Redfern
Amanda J. Redfern
LJLesley Jones
Lesley Jones